



## Possible Biomarkers in Oral Tumors and Their Clinical Significance

Guest Editor:

**Prof. Dr. Daisuke Uchida**

Department of Oral and  
Maxillofacial Surgery, Ehime  
University Graduate School of  
Medicine, 454 Shitsukawa, Toon  
791-0295, Ehime, Japan

Deadline for manuscript  
submissions:

**closed (30 November 2024)**

### Message from the Guest Editor

Oral tumors are generally easy to access by visual inspection and palpation, and most definitive diagnoses are determined by the histopathological examination after biopsies. However, the diagnosis may often be difficult due to their histopathological varieties, especially in tumors originated from tooth germ, minor salivary gland, and mesenchyme, and so on.

On the other hand, squamous cell carcinoma (SCC) is a typical malignancy in the oral cavity, the definitive diagnosis is comparatively easy because of their accessibility and characteristic histology. Although oral SCC is generally treated with surgery, radiotherapy, chemotherapy, immunotherapy, or their combination, the prognosis and the prediction of therapeutic effect are mainly determined by the histopathological degree of invasion and differentiation. Concerning the biomarker for oral SCC, serum SCC antigen is clinically applied but is not reliable as a sensitive biomarker.

In this special issue, researchers who are a head and neck oncologist and has a wealth of basic data will discuss biomarkers that are expected to be applied clinically in relation to the diagnosis, recurrence, metastasis, or prognosis of oral tumors.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)